+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Bone Pain And Bone Targeting Agent (Bta) Treatment Patterns In Patients With Bone Metastases (Bms) From Breast Cancer (Bc) In Real World Setting In Europe



Bone Pain And Bone Targeting Agent (Bta) Treatment Patterns In Patients With Bone Metastases (Bms) From Breast Cancer (Bc) In Real World Setting In Europe



Value in Health 18(7): A493




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057317354

Download citation: RISBibTeXText

PMID: 26532765

DOI: 10.1016/j.jval.2015.09.1372


Related references

Bone Pain And Bone Targeting Agent (Bta) Treatment Pattern In Patients With Bone Metastases (Bms) From Prostate Cancer (Pc) In Real World Setting In Europe. Value in Health 18(7): A493, 2015

Bone Targeting Agent (Bta) treatment patterns and the impact of Bone Metastases (Bms) on advanced breast cancer patients in a real world setting. European Journal of Cancer 51: S211-S212, 2015

Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries. Journal of Bone Oncology 11: 1-9, 2018

Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States. Current Medical Research and Opinion 35(3): 375-381, 2019

Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases. Breast Cancer 24(2): 245-253, 2017

A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe. Journal of Bone Oncology 14: 100212, 2019

Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clinical Chemistry 45(8 Pt 1): 1240-1247, 1999

Bone pain palliation with strontium-89 in breast cancer patients with bone metastases and refractory bone pain. European Journal of Nuclear Medicine 22(10): 1101-1104, 1995

Redox and pH dual sensitive bone targeting nanoparticles to treat breast cancer bone metastases and inhibit bone resorption. Nanoscale 9(19): 6264-6277, 2017

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. Supportive Care in Cancer 23(4): 1157-1168, 2015

Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study. Nuklearmedizin. Nuclear Medicine 55(5): 188-195, 2016

Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. Annals of Oncology 26(11): 2205-2213, 2015

Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. Annals of Oncology 29(5): 1329-1330, 2018

Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain. Journal of Pain and Symptom Management 38(2): 244-257, 2009

A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain. American Journal of Therapeutics 18(5): 340-342, 2011